On the other hand, Frank et al. found Glycine-β-muricholic acid (Gly-MCA), an intestine-specific FXR inhibitor, reduced obesity and associated metabolic dysfunction through inhibition of ceramide metabolism [161]. The gene discussed is NR1H4; the disease is obesity due to melanocortin 4 receptor deficiency.